Management of psoriatic arthritis: The therapeutic interface between rheumatology and dermatology

被引：28

作者：

Mease P. ^{[1
]}

机构：

[1] Division of Rheumatology Research, Swedish Medical Center, University of Washington School of Medicine, Seattle, WA 98104

来源：

Current Rheumatology Reports | 2006年 / 8卷 / 5期

关键词：

Psoriasis; Ankylose Spondylitis; Etanercept; Adalimumab; Psoriatic Arthritis;

D O I：

10.1007/s11926-006-0064-9

中图分类号：

学科分类号：

摘要：

Psoriatic arthritis is an inflammatory arthritis, which occurs in up to 30% of individuals with psoriasis. Dermatologists and other physicians treating psoriasis are in an ideal position to screen for the condition, and with rheumatologists, strategize optimal therapy. Mild skin and joint manifestations may be treated effectively with topical agents, ultraviolet light therapy, and nonsteroidal anti-inflammatory drugs. More severe manifestations of the disease, including progressive peripheral joint damage, spine disease, enthesitis, dactylitis, and severe skin changes, require systemic therapy. Traditional systemic agents include methotrexate, sulfasalazine, and cyclosporine. When these agents are not adequate or not tolerated, new biologic agents, particularly antitumor necrosis factor (TNF) compounds, have shown significant and enduring benefit in all disease domains, improvement in quality of life and function, and inhibition of progressive joint damage. Copyright © 2006 by Current Science Inc.

引用

页码：348 / 354

页数：6

共 63 条

[1]

Husted J.A., Gladman D.D., Farewell V.T., Cook R.J., Health-related quality of life of patients with psoriatic arthritis: A comparison with patients with rheumatoid arthritis, Arthritis Rheum, 45, pp. 151-158, (2001)

[2]

Wong K., Gladman D.D., Husted J., Et al., Mortality studies in psoriatic arthritis: Results from a single outpatient clinic. Causes and risk of death, Arthritis Rheum, 40, pp. 1868-1872, (1997)

[3]

Moll J., Wright V., Psoriatic arthritis, Semin Arthritis Rheum, 3, pp. 55-78, (1973)

[4]

Helliwell P., Taylor W., Classification and diagnostic criteria for psoriatic arthritis, Ann Rheum Dis, 64, SUPPL. 2, (2005)

[5]

Taylor W., Marchesoni A., Arreghini M., Et al., A comparison of the performance characteristics of classification criteria for the diagnosis of psoriatic arthritis, Semin Arthritis Rheum, 34, pp. 575-584, (2004)

[6]

Taylor W., ClASsification criteria for Psoriatic ARthritis: Development of new criteria from a large international study, Arthritis Rheum, 54, pp. 2665-2673, (2006)

[7]

Leonard D.G., O'Duffy J.D., Rogers R.S., Prospective analysis of psoriatic arthritis in patients hospitalized for psoriasis, Mayo Clin Proc, 53, pp. 511-518, (1978)

[8]

Shbeeb M., Uramoto K.M., Gibson L.E., Et al., The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982-1991, J Rheumatol, 27, pp. 1247-1250, (2000)

[9]

Salonen S., Spring Symposium of the European Academy of Dermatology and Venereology, (2003)

[10]

Gelfand J.M., Gladman D.D., Mease P.J., Et al., Epidemiology of psoriatic arthritis in the population of the United States, J Am Acad Dermatol, 53, (2005)

← 1 2 3 4 5 6 7 →